UNSPSC 51312202: Cyproheptadine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2YHB6175DO, chemically known as 5-(1-methylpiperidylidene-4)-5h-dibenzo(a,d)cyclopheptene but generally known as cyproheptadine, which bears US NIH Compound Identifier 2913. European Medicines Agency schedules Cyproheptadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06875MIG.

UNSPSC 51312202 Cyproheptadine is a Commodity code nominally identifying a single antihistamine product, but recent state and local procurement activity under this code does not reflect purchases of cyproheptadine itself. Instead, the code appears to capture a broader range of pharmaceutical procurement, including naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products procured through cooperative purchasing vehicles and direct-to-manufacturer programs. State and local buyers soliciting under this code span county health departments, state HHS commissions, and cooperative purchasing alliances serving multiple jurisdictions. The work being solicited includes annual supply agreements for naloxone and harm-reduction systems, cooperative purchasing frameworks for generic pharmaceuticals distributed through authorized wholesalers, and exploratory procurements to establish direct relationships between state pharmacy benefit programs and manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels.

Recent activity reflects a geographic mix centered on the Southeast and Upper Midwest, with Florida counties (Seminole County) and Texas state agencies (Texas Health and Human Services Commission) conducting recent solicitations alongside cooperative purchasing efforts led by Minnesota and serving multiple states including Oregon. The Seminole County IFB 60459723LAS, posted June 30, 2026, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline and quarterly deliveries to a county health facility. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP S1070000015802, posted January 20, 2026, established multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026, requiring manufacturers to supply through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC. The Texas Health and Human Services Commission issued RFI HHS0017013 on March 27, 2026 to gather market intelligence on direct-to-manufacturer pharmacy prescription programs, with responses due April 3, 2026, as a preliminary information-gathering phase preceding formal procurement specification and contracting.